Posted by Michael Wonder on 09 May 2019
Lower price for MS drug paves the way for positive recommendation from NICE
9 May 2019 - A new, lower price for a drug to treat a rarer form of multiple sclerosis in adults has paved the way for its approval by NICE.
In its final draft guidance published today, NICE has reversed its previous draft decision not to recommend ocrelizumab (Ocrevus, Roche) for treating primary progressive multiple sclerosis (PPMS) in adults.
This follows an agreement between the company and NHS England on the terms of a new commercial arrangement which will make ocrelizumab, the first disease-modifying treatment for PPMS, available at a lower price. The details of the commercial arrangement are confidential.
